標題: Titlebook: Diagnosis and Management of Pulmonary Hypertension; James R. Klinger,Robert P. Frantz Book 2015 Springer Science+Business Media New York 2 [打印本頁] 作者: 可樂 時間: 2025-3-21 18:58
書目名稱Diagnosis and Management of Pulmonary Hypertension影響因子(影響力)
書目名稱Diagnosis and Management of Pulmonary Hypertension影響因子(影響力)學(xué)科排名
書目名稱Diagnosis and Management of Pulmonary Hypertension網(wǎng)絡(luò)公開度
書目名稱Diagnosis and Management of Pulmonary Hypertension網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Diagnosis and Management of Pulmonary Hypertension被引頻次
書目名稱Diagnosis and Management of Pulmonary Hypertension被引頻次學(xué)科排名
書目名稱Diagnosis and Management of Pulmonary Hypertension年度引用
書目名稱Diagnosis and Management of Pulmonary Hypertension年度引用學(xué)科排名
書目名稱Diagnosis and Management of Pulmonary Hypertension讀者反饋
書目名稱Diagnosis and Management of Pulmonary Hypertension讀者反饋學(xué)科排名
作者: 熱心 時間: 2025-3-21 23:32 作者: 新娘 時間: 2025-3-22 02:09 作者: Counteract 時間: 2025-3-22 04:44
Hypoxic Pulmonary Hypertension, lung disease, and inflammation contribute to increased pulmonary vascular tone and remodeling. Diagnosis of pulmonary vascular disease in patients with lung disease may be especially challenging due to the lack of specificity of common complaints of dyspnea and inaccuracy of echocardiographic estim作者: 自然環(huán)境 時間: 2025-3-22 11:34
Pulmonary Hypertension in Chronic Heart and Lung Disease,ompanies hypoxic/parenchymal lung disease (Group 3). The phenotypic and hemodynamic spectrum of pulmonary hypertension in these settings is enormous, and the clinician is often left with uncertainty regarding the appropriate evaluation and management of these patients. A comprehensive understanding 作者: 圍巾 時間: 2025-3-22 14:51
Chronic Thromboembolic Pulmonary Hypertension,ulmonary embolic events. Despite this recognized complication of acute thromboembolic disease, this clinical entity remains underdiagnosed. The importance of diagnosing CTEPH in any pulmonary hypertensive patient centers on the realization that, with surgical thromboendarterectomy, a potential cure 作者: 圍巾 時間: 2025-3-22 19:22 作者: 彩色 時間: 2025-3-22 21:42 作者: Visual-Field 時間: 2025-3-23 05:15 作者: 吞下 時間: 2025-3-23 09:21
Pulmonary Hemodynamics and Right Heart Catheterization, ultimately right heart catheterization. Proper interpretation of the considerable data that is generated by this process requires a firm working knowledge of the pulmonary circulation and right ventricle along with major factors that can affect pulmonary vascular tone and cardiac output. This chapt作者: Brocas-Area 時間: 2025-3-23 10:28
Cardiopulmonary Exercise Testing in Pulmonary Hypertension,of cardiopulmonary exercise testing (CPET) has allowed an early diagnosis of PAH in “at risk” patients or those with suggestive clinical findings. CPET can quantify the degree of exercise impairment, and rule out a pulmonary mechanical limit to exercise. It can also be used to monitor disease progre作者: 強制性 時間: 2025-3-23 15:03 作者: nitroglycerin 時間: 2025-3-23 21:11
Prostacyclin Therapy for Pulmonary Arterial Hypertension,r a long time, the only treatment specifically approved for this devastating disease. As new therapies have emerged for PAH in recent years, the class of prostacyclins has also evolved and several formulations of different prostacyclin analogs, using various routes of delivery, have been tested and 作者: Nmda-Receptor 時間: 2025-3-23 23:03 作者: graphy 時間: 2025-3-24 03:06
Modulation of cGMP Synthesis and Metabolism, soluble or particulate guanylate cyclase by NO or NP, respectively. The primary downstream target of cGMP is cGMP-dependent kinase (PKG) which acts at a variety of intracellular sites to inhibit vasoconstriction, proliferation and hypertrophic responses and phosphodiesterases that are responsible f作者: Neuralgia 時間: 2025-3-24 07:41
Combination Therapy for the Treatment of Pulmonary Arterial Hypertension,d most patients will experience progression of their disease despite treatment. Presently available medications target four different cellular signaling pathways that have been implicated in the pathogenesis of PAH. It is unclear to what extent each pathway contributes to the progression of pulmonar作者: 季雨 時間: 2025-3-24 11:51
Investigative Therapies in Pulmonary Arterial Hypertension, to treat the disease, no cure is presently available. New treatments for PAH that are able to reverse the abnormal pulmonary vascular remodeling that is responsible for much of this disease are badly needed. To accomplish this goal, novel therapies that target many of the dysfunctional pathways tha作者: Clinch 時間: 2025-3-24 16:41 作者: Subdue 時間: 2025-3-24 21:33 作者: VAN 時間: 2025-3-25 03:06
Validation of IP Security and Trustapies. This chapter highlights much of our understanding of the basic pathobiology underlying PAH including genetic underpinnings, vasoactive substances, alterations in cell proliferation and apoptosis, inflammation, thrombosis, and endocrine factors.作者: Abnormal 時間: 2025-3-25 03:50
Anomalous Behaviour in Embedded Systemsbetween 30 and 41 % have been reported. Given their fragile hemodynamic status, understanding the pathogenesis of RV failure secondary to PH is critical for RV rescue and successful treatment of these patients. In this chapter, we will discuss the pathophysiology of RV failure and management of PH and RV failure in the ICU.作者: 離開 時間: 2025-3-25 08:47 作者: 吹氣 時間: 2025-3-25 13:56 作者: travail 時間: 2025-3-25 16:03
Prostacyclin Therapy for Pulmonary Arterial Hypertension,shown to be efficacious in PAH. This chapter reviews the pharmacology of prostacyclins and the results of pivotal clinical trials testing various formulations. Lastly, it examines practical aspects of dosing, management of side effects, and expectations of treatment goals.作者: NAV 時間: 2025-3-25 20:07 作者: 分發(fā) 時間: 2025-3-26 03:11
Analyzing Circuit Layout to Probing Attackll review the epidemiology and pathogenesis of PH associated with chronic lung disease and provide an approach to evaluation and management including the identification and selection of some patients who may benefit from currently available pulmonary vasodilator therapies.作者: filial 時間: 2025-3-26 05:41 作者: 到婚嫁年齡 時間: 2025-3-26 09:51
Po-Rong Chang,Bor-Chin Wang,Tan-Hsu Tanrs that provide a comprehensive view of the underlying pathophysiology of PH. For example, several signature findings, well studied and validated, will help in differentiating the two major causes of PH, namely, PH that is caused by pulmonary venous hypertension (PH.) from PH that is caused by pulmonary vascular disease (PH.).作者: 心痛 時間: 2025-3-26 15:02
Anomaly Detection in an Embedded Systemhese abnormalities are reviewed along with data, where available, from animal studies and small clinical trials that have attempted to treat pulmonary vascular disease through manipulation of these pathways.作者: 種子 時間: 2025-3-26 19:41
Truss: A Standard Verification Frameworkand emergent mechanical interventions for right ventricular failure. This chapter is intended to be a guide for all physicians managing the perioperative care of patients with pulmonary hypertension, with an emphasis on noncardiac surgery.作者: ordain 時間: 2025-3-26 22:33
Hypoxic Pulmonary Hypertension,ll review the epidemiology and pathogenesis of PH associated with chronic lung disease and provide an approach to evaluation and management including the identification and selection of some patients who may benefit from currently available pulmonary vasodilator therapies.作者: 名次后綴 時間: 2025-3-27 04:29
Chronic Thromboembolic Pulmonary Hypertension,tional status. This chapter presents an updated review of the epidemiology, pathophysiology, clinical presentation, assessment, and treatment options for those patients with chronic thromboembolic pulmonary hypertension.作者: 傲慢人 時間: 2025-3-27 06:50
Echocardiography,rs that provide a comprehensive view of the underlying pathophysiology of PH. For example, several signature findings, well studied and validated, will help in differentiating the two major causes of PH, namely, PH that is caused by pulmonary venous hypertension (PH.) from PH that is caused by pulmonary vascular disease (PH.).作者: 大包裹 時間: 2025-3-27 11:25 作者: 在前面 時間: 2025-3-27 16:23 作者: fabricate 時間: 2025-3-27 18:16
2197-7372 nts.This book provides an overview of pulmonary hypertensive diseases, the current understanding of their pathobiology, and a contemporary approach to diagnosis and treatment. It discusses the definition and classification of these disorders and the epidemiology of pulmonary arterial hypertension (P作者: Capture 時間: 2025-3-27 23:25 作者: Macronutrients 時間: 2025-3-28 06:09 作者: Adulterate 時間: 2025-3-28 08:07
Siddharth Garg,Jeyavijayan (JV) Rajendranshown to be efficacious in PAH. This chapter reviews the pharmacology of prostacyclins and the results of pivotal clinical trials testing various formulations. Lastly, it examines practical aspects of dosing, management of side effects, and expectations of treatment goals.作者: 很像弓] 時間: 2025-3-28 11:44 作者: opinionated 時間: 2025-3-28 16:21
Diagnosis and Management of Pulmonary Hypertension978-1-4939-2636-7Series ISSN 2197-7372 Series E-ISSN 2197-7380 作者: braggadocio 時間: 2025-3-28 22:21 作者: 墊子 時間: 2025-3-29 01:31 作者: 聯(lián)合 時間: 2025-3-29 05:37 作者: scrutiny 時間: 2025-3-29 09:00
Xiaolong Guo,Raj Gautam Dutta,Yier Jinrterial pressure to 25 mmHg or greater. Currently, the pulmonary hypertensive diseases are organized into five groups that include (1) pulmonary arterial hypertension, (2) pulmonary hypertension owing to left-sided heart disease, (3) pulmonary hypertension owing to chronic lung disease, (4) chronic 作者: frivolous 時間: 2025-3-29 11:38 作者: 拖債 時間: 2025-3-29 18:12
Analyzing Circuit Layout to Probing Attack lung disease, and inflammation contribute to increased pulmonary vascular tone and remodeling. Diagnosis of pulmonary vascular disease in patients with lung disease may be especially challenging due to the lack of specificity of common complaints of dyspnea and inaccuracy of echocardiographic estim作者: Control-Group 時間: 2025-3-29 21:56
Nicole Fern,Kwang-Ting (Tim) Chengompanies hypoxic/parenchymal lung disease (Group 3). The phenotypic and hemodynamic spectrum of pulmonary hypertension in these settings is enormous, and the clinician is often left with uncertainty regarding the appropriate evaluation and management of these patients. A comprehensive understanding 作者: 劇毒 時間: 2025-3-30 03:48
Xiaolong Guo,Raj Gautam Dutta,Yier Jinulmonary embolic events. Despite this recognized complication of acute thromboembolic disease, this clinical entity remains underdiagnosed. The importance of diagnosing CTEPH in any pulmonary hypertensive patient centers on the realization that, with surgical thromboendarterectomy, a potential cure 作者: 迷住 時間: 2025-3-30 04:19 作者: Cupidity 時間: 2025-3-30 08:22
High Performance Fuzzy Processorsvascular resistance, cardiac output, or combinations thereof. When the mechanism of PH is related to an elevation in vascular resistance, the term pulmonary . hypertension is used, and may occur in the presence or absence of certain associated conditions. Identification of this subset is important a作者: 傻瓜 時間: 2025-3-30 14:44 作者: 他去就結(jié)束 時間: 2025-3-30 18:16
pRAM: The Probabilistic RAM Neural Processor ultimately right heart catheterization. Proper interpretation of the considerable data that is generated by this process requires a firm working knowledge of the pulmonary circulation and right ventricle along with major factors that can affect pulmonary vascular tone and cardiac output. This chapt作者: 印第安人 時間: 2025-3-30 22:09 作者: somnambulism 時間: 2025-3-31 03:02
Siddharth Garg,Jeyavijayan (JV) Rajendranspecific, time-honored treatments in an effort to help these unfortunate patients. While the role of these therapies has not been rigorously studied they are still commonly used as adjuncts to PAH-specific therapies. This chapter outlines the logic and rationale behind the use of digoxin therapy, an作者: 頂點 時間: 2025-3-31 05:40
Siddharth Garg,Jeyavijayan (JV) Rajendranr a long time, the only treatment specifically approved for this devastating disease. As new therapies have emerged for PAH in recent years, the class of prostacyclins has also evolved and several formulations of different prostacyclin analogs, using various routes of delivery, have been tested and 作者: UNT 時間: 2025-3-31 09:18 作者: 是貪求 時間: 2025-3-31 13:55 作者: Respond 時間: 2025-3-31 20:43
Yildiran Yilmaz,Viet-Hoa Do,Basel Halakd most patients will experience progression of their disease despite treatment. Presently available medications target four different cellular signaling pathways that have been implicated in the pathogenesis of PAH. It is unclear to what extent each pathway contributes to the progression of pulmonar作者: Flatter 時間: 2025-4-1 00:30
Anomaly Detection in an Embedded System to treat the disease, no cure is presently available. New treatments for PAH that are able to reverse the abnormal pulmonary vascular remodeling that is responsible for much of this disease are badly needed. To accomplish this goal, novel therapies that target many of the dysfunctional pathways tha作者: Hyperplasia 時間: 2025-4-1 02:18
